Company profile

Bio-Thera Solutions

Privately held: no public share price

Assets

(7 total)
7Total Assets
2Approved
3Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
BAT1706
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung Cancer
tocilizumab(Actemra / RoActemra)
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis
BAT1806No recent activity
Phase 3
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis
BAT3306
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
BAT5906
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
BAT6026
Phase 2
OX40Monoclonal antibody
Atopic Dermatitis
BAT2606No recent activity
Phase 1
IL-5
Asthma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.